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Parkinson’s disease (PD) is an age-related neurodegenerative disorder charac-
terized by motor symptoms such as tremor, slowness of movement, rigidity,
and postural instability, as well as non-motor features like sleep disturbances,
loss of ability to smell, depression, constipation, and pain. Motor symptoms are
caused by depletion of dopamine in the striatum due to the progressive loss of
dopamine neurons in the substantia nigra pars compacta. Approximately 10%
of PD cases are familial arising from genetic mutations in α-synuclein, LRRK2,
DJ-1, PINK1, parkin, and several other proteins. The majority of PD cases are,
however, idiopathic, i.e., having no clear etiology. PD is characterized by pro-
gressive accumulation of insoluble inclusions, known as Lewy bodies, mostly
composed of α-synuclein and membrane components. The cause of PD is cur-
rently attributed to cellular proteostasis deregulation and mitochondrial dys-
function, which are likely interdependent. In addition, neuroinflammation is
present in brains of PD patients, but whether it is the cause or consequence of
neurodegeneration remains to be studied. Rodents do not develop PD or PD-like
motor symptoms spontaneously; however, neurotoxins, genetic mutations, vi-
ral vector-mediated transgene expression and, recently, injections of misfolded
α-synuclein have been successfully utilized to model certain aspects of the dis-
ease. Here, we critically review the advantages and drawbacks of rodent PD
models and discuss approaches to advance pre-clinical PD research towards
successful disease-modifying therapy. © 2020 The Authors.
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INTRODUCTION
Disease Phenotypes
Parkinson’s disease (PD) is a progressive
neurodegenerative disease lacking disease-
modifying therapies, and current drug treat-
ments are symptomatic. The motor symptoms
of PD are rigidity, tremor, postural instabil-
ity, and bradykinesia, but also non-motor signs
such as lack of motivation, depression, sleep
disorders, loss of smell, cognitive impairment,
and constipation are present (Bartels & Leen-
ders, 2009; Halliday, Lees, & Stern, 2011;
Weintraub & Burn, 2011). PD is characterized
by slow and progressive age-related degenera-
tion of dopaminergic neurons in the substantia
nigra pars compacta (SNpc) projecting to the
dorsal striatum, which are part of the circuitry
controlling motor learning and movement
(Moore, West, Dawson, & Dawson, 2005).
Why do dopaminergic neurons in the SNpc
start to die? We do not know the exact answer
to this question. Considering that most PD
cases are idiopathic it is likely that there is a
deregulation of basic cellular functions that
cause the disease. The loss of dopaminergic
neurons in familial forms of PD correlates
with mutations in genes such as SNCA,
Parkin/PARK2, ubiquitin carboxy terminal
hydrolase-1 (UCHL1), PINK1, DJ-1/PARK7,
and LRRK2 (Gasser, Hardy, & Mizuno, 2011;
Nalls et al., 2014). In addition, several cellular
and molecular mechanisms such as mitochon-
drial dysfunction, proteostasis, lysosomal
and autophagy failures, oxidative stress, and
neuroinflammation may underlie the dis-
ease (Hirsch & Hunot, 2009; Obeso et al.,
2010; Thomas & Beal, 2007; Valente, Arena,
Torosantucci, & Gelmetti, 2012). Since there
is no single cause for the neurodegeneration,
one option is that selective vulnerability
of SNpc neurons–over other dopaminergic
neurocircuitry–is caused by their physiologi-
cal properties. For example, L-type Ca2+ and
K+ ATP channels mediating the pacemaking
activity specific for SNpc dopaminergic neu-
rons can cause increased stress (Chan et al.,
2007; Guzman et al., 2010; Liss et al., 2005;
Mosharov et al., 2009; Nedergaard, Flatman,
& Engberg, 1993). In addition, extensive
arborization of nigrostriatal dopaminergic
neurons as compared to other neurons (Mat-
suda et al., 2009) increases their demand for
energy, proteostasis, and lysosomal functions.
The presence of α-synuclein-containing
insoluble inclusions in neuronal soma or neu-
rites, called Lewy bodies or Lewy neurites,
respectively, is the major histopathological
hallmark of PD (Spillantini, Crowther, Jakes,
Hasegawa, & Goedert, 1998). Under normal
conditions, α-synuclein, an abundant pro-
tein located in presynaptic terminals, exists in
monomeric, oligomeric, and aggregated forms
in equilibrium (Bengoa-Vergniory, Roberts,
Wade-Martins, & Alegre-Abarrategui, 2017).
However, under unknown pathological con-
ditions, Lewy bodies and Lewy neurites are
formed and spread spatially and temporally
in a prion-like fashion (Braak et al., 2003;
Kordower, Chu, Hauser, Freeman, & Olanow,
2008; Li et al., 2008). Although α-synuclein
inclusions in sporadic PD as well as muta-
tions in the SNCA gene coding this protein
point out its relation to the disease pathology,
mechanisms linking Lewy body formation
and neurodegeneration are still poorly under-
stood. There are several pre-clinical studies
that suggest the toxicity of α-synuclein inclu-
sions causes degeneration of dopaminergic
neurons. In 2003, Heiko Braak and colleagues
proposed a classification (Braak stages) of the
degree of progressive PD pathology based on
the presence of Lewy bodies (Braak et al.,
2003). However, a review by Robert Burke
and colleagues already in 2008 noticed that
there is no correlation between Braak stages
and clinical severity of PD (Burke, Dauer, &
Vonsattel, 2008). Moreover, a post-mortem
study comparing Lewy bodies and dopamin-
ergic neuron density in the SNpc showed that
neuronal density was not related to the Braak
PD stage or Lewy body densities in the cortex
(Parkkinen et al., 2011). In addition, the age at
death or duration of disease did not have any
effect on the proportion of nigral dopamin-
ergic neurons with Lewy bodies (Parkkinen
et al., 2011). Thus, it is rather likely that Lewy
bodies are not the toxic component responsi-
ble for cell death. However, Lewy bodies can
cause functional deficits in neurons, which
may lead to many of the symptoms of PD,
although this needs to be studied further.
Dopaminergic Neurodegeneration—
Losing the Phenotype Versus Cell
Death
We have previously reviewed the concept
of neurorestorative therapies (Domanskyi
et al., 2015). It is based on clinical and ani-
mal studies revealing that the “dying back”
degeneration of nigrostriatal dopaminergic
neurons starts from the caudate putamen (also
known as striatum) and progresses to cell
bodies in the SNpc (Bernheimer, Birkmayer,
Hornykiewicz, Jellinger, & Seitelberger,
1973; Kish, Shannak, & Hornykiewicz, 1988;
Airavaara et al.
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Scherman et al., 1989). In dying nigrostriatal
dopaminergic neurons labeled with green
fluorescent protein (GFP), GFP fluorescence
was still detected after the phenotypic markers
were lost (Cheng et al., 2011). In addition,
axotomized cholinergic neurons first lose
their phenotypic markers, but retain cytoar-
chitecture, before they die (Hagg, Manthorpe,
Vahlsing, & Varon, 1988; Williams, 1996). A
similar phenomenon occurs in toxin models
(Airavaara, Voutilainen, Wang, & Hoffer,
2012; Schober, 2004) and in genetic rodent
models of PD (Domanskyi, Alter, Vogt, Gass,
& Vinnikov, 2014; Ekstrand et al., 2007; Y.
Li et al., 2009; Rieker et al., 2011). More-
over, the estimations carried out by Richard
Burke and colleagues show that at the onset
of PD symptoms only approximately 30% of
SNpc dopaminergic neurons are lost (Cheng,
Ulane, & Burke, 2010), indicating that the
majority of dopaminergic neurons are viable
at this time point. This loss of phenotype
phenomenon before actual neuronal death
gives a possibility to apply therapies aiming
to restore the dopaminergic phenotype and
function as long as neuronal cell bodies are
still present. This concept is nevertheless dif-
ferent from regeneration therapies where new
neurons are induced either from endogenous
or transplanted neuronal precursors aiming
at repairing and replacing the degenerating
dopamine cells or circuitry.
In neurorestoration, there are dopaminergic
neurons that do not have functional synaptic
contacts and axons have lost their phenotype
in a gradient manner progressing from the
striatum. These neurons can be targets for
neurorestorative disease-modifying therapy.
The longer and faster neurodegeneration
progresses, the smaller the number of neu-
rons will be that can be restored. However,
when the neurodegeneration has progressed
too far there may be no more possibility to
restore these cells. Naturally, PD progresses
at different rates and we need more quanti-
tative measures to follow the progression of
neurodegeneration in PD patients.
How to Measure Neuroprotection
and Neurorestoration of SNpc
Dopaminergic Neurons?
Neuroprotective and neurorestorative ef-
fects need to be shown in multiple ways. In
order to conclude that a given treatment is
protective, one needs to quantify dopamin-
ergic neurite and cell soma restoration, and
protection of functionality needs to be shown
with behavioral analysis. The advantage
of animal PD models is that because the
nigrostriatal dopamine system has such a
strong role in controlling behavior, neurode-
generation can be estimated by measuring
behavioral deficits. The most used behavioral
tests for a unilateral lesion are cylinder test,
D-amphetamine-induced rotations, and the
staircase test (Asakawa et al., 2016; Montoya,
Campbell-Hope, Pemberton, & Dunnett,
1991). Behavioral functional recovery needs
to correlate with neurite density or dopamine
concentrations in the striatum. Neurite density
can be measured with markers such as tyro-
sine hydroxylase (TH), VMAT, or dopamine
transporter (DAT), with TH being the most
sensitive for up or downregulation with var-
ious stimuli (Kumer & Vrana, 1996; Tenen-
baum & Humbert-Claude, 2017). Behavioral
effects do not need to directly correlate with
dopaminergic neuron numbers in SNpc, but
naturally the neuroprotection needs to be
shown at the neuron number level as well.
Conversely, several studies have shown the
loss of neurites or cell bodies in rodent PD
models, but without having behavioral deficits
the data does not make much sense. If the
dopaminergic neurons are depleted and the
neurites gone, the mobility of animals should
be minimal. Indeed, the animal should have
severely reduced mobility, similar to Arvid
Carslsson’s rabbits after reserpine-induced
parkinsonism, where reserpine depletes amine
stores (Carlsson, 2001; Carlsson, Lindqvist,
& Magnusson, 1957). However, one cannot
claim a neuroprotective effect with behavioral
improvement alone unless it is paired with a
cellular and molecular outcome. There can
be many reasons for the treatment to cause
behavioral improvement after dopaminergic
degeneration, other than direct effects on the
nigrostriatal dopamine system. Thus, while
behavioral responses after a unilateral or bilat-
eral lesion can be measured with established
tests, without quantification of dopaminergic
neurite density and neuron numbers, these
tests are not enough to draw conclusions on
neuroprotection and neurorestoration after a
given treatment. There is much that we can do
as a field to improve the quality of our studies
in this regard.
NEUROTOXIN-INDUCED MODELS
6-Hydroxydopamine (6-OHDA)
Dopamine is synthesized enzymatically,
by TH and AADC, from the amino acids L-
tyrosine and L-phenylalanine (Meiser, Weindl,
& Hiller, 2013; Senoh &Witkop, 1959). First,
Airavaara et al.
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Figure 1 Catecholamine synthesis, alternative dopamine synthesis, and select toxic derivatives related to
dopamine. 6-OHDA: 6-hydroxydopamine, AADC: aromatic l-amino acid decarboxylase, CYP2D: cytochrome
P450 2D, L-DOPA: L-dihydroxyphenylalanine, ROS: reactive oxygen species.
L-phenylalanine is oxidized into L-tyrosine by
phenylalanine hydroxylase, which is oxidized
into DOPA by TH and finally DOPA is de-
carboxylated into dopamine by AADC. The
alternative synthesis of dopamine happens by
AADC decarboxylating L-phenylalanine into
phenylethylamine which is oxidized into tyra-
mine, or L-tyrosine into tyramine. Tyramine
is then oxidized into dopamine by CYP2D.
Dopamine is further oxidized into nora-
drenaline and both dopamine and DOPA can
be oxidized enzymatically into toxic metabo-
lites, by catalysis (Fe3+) or by reactive oxygen
species (ROS) to the highly reactive ortho-
quinones DOPA-quinone and dopamine-
quinone. Dopamine-quinones are precursors
to many neurotoxins that mainly cause ox-
idative stress and mitochondrial dysfunction
by blocking the function of the electron
transport chain. If iron is present, dopamine-
quinone can react to form the neurotoxin
6-hydroxydopamine (6-OHDA) (Graham,
1978; Napolitano, Pezzella, & Prota, 1999)
(Fig. 1).
6-OHDA internalizes to dopaminergic and
noradrenergic neurons through the DAT and
noradrenaline transporters (NET), respec-
tively, and its cytotoxic effects are thought to
bemediatedmainly by oxidative stress, caused
by the generation of ROS by either blocking
the mitochondrial respiratory chain complex
I or formation of hydrogen peroxide and vari-
ous radicals, but the exact mechanisms are still
unclear (Glinka, Gassen, & Youdim, 1997;
Luthman, Fredriksson, Sundstrom, Jonsson,
& Archer, 1989; Mazzio, Reams, & Soliman,
2004; Saner & Thoenen, 1971). Although
it is selectively taken up by these neurons,
it can cause some damage to other neurons
non-specifically. A plethora of other effects
have been associated with 6-OHDA, for ex-
ample, neuroinflammation and activation of
microglia, which may contribute to the degen-
eration of dopaminergic neurons (CicchettiAiravaara et al.
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et al., 2002). It should also be noted that in
many protocols 6-OHDA is diluted in sterile
saline containing ascorbic acid, and thus,
acidic solution itself can cause activation of
glial cells.
6-OHDA was discovered to cause degen-
eration of the nigrostriatal system in the late
1960s (Ungerstedt, 1968). In the 1970s, it was
used to develop the first animal model of PD
(Ungerstedt, 1971b; Ungerstedt &Arbuthnott,
1970; Ungerstedt, Ljungberg, & Steg, 1974).
Many in vivo models using 6-OHDA have
been established as it works well in various an-
imals, mainly rodents (mice, rats, and guinea
pigs), cats, and primates. There are three
main sites in the nigrostriatal pathway where
6-OHDA can be injected for modeling PD:
the medial forebrain bundle (MFB), SNpc,
and striatum (Faull & Laverty, 1969; Hefti,
Melamed, & Wurtman, 1980; Kirik, Rosen-
blad, & Bjorklund, 1998; Perese, Ulman,
Viola, Ewing, & Bankiewicz, 1989; Sauer
& Oertel, 1994; Stanic, Finkelstein, Bourke,
Drago, & Horne, 2003). Since dopaminergic
cell bodies are located in the SNpc and their
projecting axonal terminals in the striatum,
the most prominent lesion and rapid cell death
(within days) comes when injecting 6-OHDA
to the nigra/MFB, while the mildest lesion and
slower cell death (weeks) is observed when
injecting to the striatum. Unilateral lesions
are preferred as bilateral lesions have a signif-
icantly higher mortality rate due to increased
aphagia, adipsia, and seizures (Sakai & Gash,
1994; Ungerstedt, 1971a). Studies carried out
in the MFB show that apomorphine-induced
rotations are a good estimate when predicting
the lesion success, and more precise than
amphetamine-induced rotations (Hudson
et al., 1993). Follow-up studies have shown
that apomorphine at a dose of 0.05 mg/kg
works well in Fisher rats as described earlier
(Hudson et al., 1993), but in Han Wistar rats
we were not able to see similar effects with
such a low dose (Huotarinen et al., 2018).
Strain differences are common and we would
recommend this model to be adopted based
on the Hudson et al. (1993). Another issue
with apomorphine-induced rotations in MFB
lesioned animals is rapid development of sen-
sitization, and already a second injection of
apomorphine causes a robust but rather short
conditioning effect (Hudson, Fong, Boyson,
& Hoffer, 1994). This issue can be avoided by
habituating the animals before the injection of
apomorphine.
One of the first thorough characterization
and optimization studies on the striatal uni-
lateral lesion were done in the 1990s (Kirik
et al., 1998; Przedborski et al., 1995). They
observed that the lesion depends mostly on
the injection site(s) and dosage. These pa-
rameters have since been further optimized
by others for further stability (Heuer, Smith,
Lelos, Lane, & Dunnett, 2012; Penttinen
et al., 2016). Comparing various dosing reg-
imens, needles, and injection sites, we have
found that the most reliable partial lesion and
behavioral effect, analyzed by TH staining
and drug-induced rotations, was obtained by
injecting 3 × 2 μg of 6-OHDA into three
regions of the striatum of rats (Penttinen
et al., 2016). This low-dose model produces
consistent lesions, and therefore, reduces the
number of animals needed for experiments.
The disadvantage of the unilateral striatal
6-OHDA model is that it does not replicate
human PD very well as the loss of dopamin-
ergic neurons progresses fast (days-weeks)
compared to patients (years) and there is
a lack of hallmarks, such as Lewy bodies
or other filamental intraneuronal inclusions
(Muma et al., 2001; Zeng et al., 2002). 6-
OHDA does not cross the blood-brain barrier,
so it needs to be administered intracranially
(intraventricularly, intracisternally, or intrac-
erebrally) by stereotaxic injections, and the
rat is preferred as the injection sites are quite
small, and thus, requires more precision in
mice (Ungerstedt, 1968, 1971b). A nore-
pinephrine transporter (NET) inhibitor, such
as desipramine, needs to be administered
concomitantly to achieve dopaminergic se-
lectivity. 6-OHDA is also quite unstable and
light sensitive, so it should be prepared imme-
diately before the experiment and protected
from light at all times (Soto-Otero, Mendez-
Alvarez, Hermida-Ameijeiras, Munoz-Patino,
& Labandeira-Garcia, 2000). The liquid
changes color from clear to dark brown when
6-OHDA is oxidized, so the stability can be
confirmed by visual inspection.
The advantages of the unilateral striatal
6-OHDA model, however, are that it repli-
cates the degeneration of the nigrostriatal
tract and this effect is quite reproducible and
well-tolerated by the animals (Penttinen et al.,
2016). The effects on locomotion can also
be quantified reliably so it is very useful in
screening for new therapeutics aimed at restor-
ing or protecting the mesencephalic dopamine
system (Penttinen, Parkkinen, Voutilainen,
et al., 2018; Voutilainen et al., 2017). Behav-
ioral assessment is much easier with regards
to locomotor activity and the use of the con-
tralateral side as a control enables reliable
Airavaara et al.
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and physiologically relevant comparison in
biochemical assessment of the lesion (Unger-
stedt & Arbuthnott, 1970). The unilateral
6-OHDA model is also widely used in mod-
eling dyskinesias in conjunction with chronic
L-DOPA treatment (Lundblad et al., 2005;
Smith, Heuer, Dunnett, & Lane, 2012). In ad-
dition, since it is a unilateral model, there are
very few ethical concerns because the animals’
feeding and drinking behavior is not altered.
Behavioral assessment is done mostly by
drug-induced asymmetrical rotations, mainly
dopamine receptor agonists or dopamine
releasing compounds such as D-amphetamine
and apomorphine, or alternatively by the
cylinder test (where no drugs are used) (Hefti
et al., 1980; Schallert, Fleming, Leasure,
Tillerson, & Bland, 2000; Ungerstedt &
Arbuthnott, 1970). In rotations, after unilat-
eral 6-OHDA model induction, the animal
is injected with a relatively high dose of
D-amphetamine to induce ipsilateral rota-
tions or apomorphine to induce contralateral
rotations, which are quantified for a certain
amount of time, usually 2 hr at most, and
measure the locomotor deficits caused by
the loss of dopamine in the striatum. The
rotation test has received criticism due to
the usage of pharmacological agents that
may interfere and/or affect the outcome
of the studied interfering factor, especially
when they are pharmacological interventions
(Marin, Rodriguez-Oroz, & Obeso, 2006).
Animals may sensitize to amphetamines and
correlation with nigral cell loss is not very
high. Thus, in many cases the cylinder test
can be used as a non-pharmacological test or
the limb-use asymmetry test (Schallert et al.,
2000). It measures activity/novelty seeking
behavior and locomotion by quantifying the
amount and difference of ipsi- and contralat-
eral paw touches, rearings, and paw touches
after rearings for a set amount of time, usually
between 5 and 20 min, in a cylindric appa-
ratus. Other motor performance tests such
as stepping test or adhesive removal test can
also be implemented. In addition, non-motor
symptoms in the 6-OHDA models have been
assessed with various behavioral tests, some
of them producing robust effects, but not to
the same extent as the motor phenotype tests
(Bonito-Oliva, Masini, & Fisone, 2014).
1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)
Loss of dopaminergic circuitry can be
induced in C57/Bl6 mice by 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)
i.p. injections (Heikkila, Nicklas, Vyas, & Du-
voisin, 1985; Jonsson et al., 1985; Sundstrom,
Stromberg, Tsutsumi, Olson, & Jonsson,
1987). Since these studies, MPTP has been
used extensively for almost 30 years. MPTP
produces a PD-like syndrome in non-human
primates and has been shown to cause parkin-
sonism in humans. Although this toxin does
not reflect all proximal causes of PD or its
neuropathology, and clinical condition of PD
occurs progressively over many years, there
are several reasons to use this model. First,
MPTP appears to produce key aspects of the
cellular effects believed to be involved in
the motor symptoms of PD and to produce
a robust phenotype both in terms of the loss
of dopaminergic neurons and severe motor
deficits. Second, MPTP can be used in mice,
monkeys, and in tissue culture via its active
metabolite, MPP+. In mice, the MPTP model
can be divided into three categories: acute,
subacute, and progressive.
In the acute model, MPTP is given four
times at 2-hr intervals at doses between 15
and 20 mg/kg (Airavaara, Harvey, et al., 2012;
Chen et al., 2008; Jackson-Lewis & Przed-
borski, 2007). Our experience in the model is
that the PD motor phenotype can be variable
and this variation may result from the stress
status of the animal. For example, if the male
mice have been fighting the outcome of MPTP
lesion can vary. The second thing that we have
observed is that the lethality can be high and
this can be avoided by simply putting the mice
into cages without bedding and keeping them
there for a day after injections. In the subacute
model, mice receive five consecutive doses of
MPTP 25 mg/kg i.p. (Ghosh et al., 2016). The
subacute model causes less acute lethality and
the loss of dopaminergic phenotype is more
consistent. The third is a “progressive model”
of MPTP administration in which MPTP
is given every 3.5 days over 5 weeks, each
injection preceded by probenecid to increase
the retention of MPTP in the CNS (Petroske,
Meredith, Callen, Totterdell, & Lau, 2001).
This model leads to the gradual onset of
behavioral and dopaminergic impairment,
allowing an experimenter to introduce inter-
vention during the earliest neurodegeneration
stage. Also, unlike the acute MPTP model,
these mice develop α-synuclein-positive in-
clusions and changes in the folding of proteins
(Fornai et al., 2005). There seems to be some
spontaneous recovery in all of these MPTP
models, but the MPTP/probenecid model
causes the most long-lasting deficits, and
even after 6 months post MPTP/probenecid
Airavaara et al.
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almost 80% of striatal dopamine is still
depleted.
The disadvantage of MPTP is that due
to the bilateral lesion it also causes PD-
like symptoms in general mouse behavior.
Therefore, one needs to carefully take care
of nutrition and hydration status of the ani-
mals. The other disadvantage where careful
consideration needs to be taken is that this
model works well only in C57Bl6 mice.
In other mouse strains the effects are more
variable, and it does not work in rats at all.
One should also pay attention in selecting
the C57Bl6 mouse sub-strain, since some of
them are knockouts for α-synuclein (Specht
& Schoepfer, 2001). MPTP can also be used
in combination with genetic modifications;
however, due to differential sensitivity to
MPTP one should be careful when using mice
from mixed genetic backgrounds.
Lactacystin
Proteinmetabolism has been a central inter-
est in PD due to observed lysosomal dysfunc-
tion, especially after the discovery that Lewy
bodies contain misfolded proteins, such as α-
synuclein, and membrane fragments (Shah-
moradian et al., 2019; Spillantini et al., 1998).
Further discoveries of genes implicated in
familial PD and involved in the ubiquitin-
proteasome system, namely UCHL1 and
parkin, raised awareness on the importance of
protein metabolism (Kitada et al., 1998; Leroy
et al., 1998). These new insights were fol-
lowed by other findings in proteasomal dys-
function which led to the development of new
animal models of PD (McNaught & Jenner,
2001; McNaught et al., 2002; McNaught, Be-
lizaire, Jenner, Olanow, & Isacson, 2002). Pro-
teasomal inhibitors, namely lactacystin and
PSI, were found to selectively kill dopamin-
ergic neurons in the nigrostriatal system, re-
duce dopamine levels in the striatum, and
cause abnormalities in motor function. Lacta-
cystin has been tested in various animal mod-
els, notably fish, rodents, and primates and at
different administration sites, mainly, as with
6-OHDA, the SNpc, MFB, and striatum, as
well as systemically (Bentea, Verbruggen, &
Massie, 2017). Loss of dopaminergic neurons
has been reported with impaired motor behav-
ior and filamental proteinaceous inclusions in
brain regions affected by PD. However, later
studies could not reproduce most of these find-
ings, although some aspects of themodel, such
as the loss of nigral dopaminergic neurons
and accumulation of proteinaceous inclusions,
have been replicated (Savolainen, Albert,
Airavaara, & Myohanen, 2017). In addition,
the observed motor deficits were not as promi-
nent as in the original studies (Kordower et al.,
2006; Manning-Bog et al., 2006). More re-
cent studies have optimized lactacystin dosage
or used it in combination with other agents
such as LPS to observe more robust responses
(Deneyer, Albertini, Bentea, &Massie, 2019).
Pesticides
Rotenone, reported to be used as a fish poi-
son in Peru in 1929, is a pesticidic flavonoid
found in many Leguminosa plants and causes
selective nigrostriatal dopaminergic degenera-
tion by inhibiting mitochondria complex I and
proteasomal activity, causing oxidative and
proteolytic stress (Betarbet et al., 2000; Clark,
1929; Sherer et al., 2003). It causes accumula-
tion of Lewy body-like inclusions containing
ubiquitin and α-synuclein. Rotenone can be
administered by many routes as it crosses the
blood-brain barrier due to its high lipophilic
profile. Injections to the MFB cause loss
of dopamine and systemic administration
causes damage in the striatum and nigral pro-
teinaceous inclusions (Betarbet et al., 2000;
Ferrante, Schulz, Kowall, & Beal, 1997;
Heikkila et al., 1985; Ravenstijn et al., 2008).
However, most groups have noticed that only
some of the animals have nigrostriatal degen-
eration and it does not seem to work well in
other animals besides the rat. In addition, the
specificity of the damage to the nigrostriatal
system has been questioned and high accounts
of mortality reported has caused problems
in reproducibility in rotenone models of PD
(Betarbet et al., 2000; Greenamyre, Cannon,
Drolet, & Mastroberardino, 2010; Hoglinger
et al., 2003). So far, the best working models
have used repeated low dose i.p. adminis-
trations for at least 30 days, and with the
use of novel delivery vehicles have reduced
mortality and provided robust motor deficits,
which indicates that the model could be very
useful and reproducible with careful setup
and optimization (Alam & Schmidt, 2002;
Cannon et al., 2009).
Paraquat (N,N′-dimethyl-4-4′-bipirid-
inium) is a herbicidic compound that resem-
bles MPP+ and has been shown to cause
major toxicity to several organs, such as
the lungs, liver, and kidneys. In contrast to
MPP+ and despite the similarities in struc-
ture, paraquat seems to cross the blood-brain
barrier, most likely through a neutral amino
acid transporter, in an age-dependent manner
and does not require DAT to enter dopamin-
ergic neurons (Corasaniti, Defilippo, Rodino,
Airavaara et al.
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Nappi, & Nistico, 1991; Richardson, Quan,
Sherer, Greenamyre, & Miller, 2005; Shimizu
et al., 2001). Its mechanism of causing cell
death also differs from rotenone and MPP+
as it is not effective in blocking complex I.
Paraquat induces apoptosis through the intrin-
sic mitochondrial pathway and causes major
oxidative stress acting as a redox cycler and in-
hibiting the antioxidative action of glutathione
(Day, Patel, Calavetta, Chang, & Stamler,
1999; Fei, McCormack, Di Monte, & Ethell,
2008; Richardson et al., 2005). Attempts at
using it to develop PD animal models have
been conflicting as some researchers have
observed nigrostriatal loss of dopamine and
dopaminergic neurons with deficits in motor
behavior, whereas others have not observed
any of these effects using similar protocols in
mice (McCormack & Di Monte, 2003; Mc-
Cormack et al., 2002; Thiruchelvam, Brockel,
Richfield, Baggs, & Cory-Slechta, 2000).
As with proteasomal inhibitors, the pres-
ence of α-synuclein inclusions has garnered
interest in pesticide models. Further studies
demonstrated that, similar to lactacystin, com-
binations of paraquat with other compounds,
such as maneb, may provide a synergistic
effect and more robust lesions with motor
impairments (Bastias-Candia, Di Benedetto,
D’Addario, Candeletti, & Romualdi, 2015;
Caputi et al., 2015).
GENETIC MODELS
Two different, albeit interconnected, types
of genetic mouse models of PD have been
created—GWAS-based and etiological mod-
els (http://www.informatics.jax.org/disease/
DOID:14330). Several genetic variants are
associated with familial early-onset PD, the
major ones affecting α-synuclein and LRRK2
(with autosomal dominant inheritance) and
DJ-1, PINK1, and Parkin (with autosomal
recessive inheritance; see https://www.omim.
org/phenotypicSeries/PS168600 for the
regularly updated list of genetic variants
associated with PD) (Klein & Westenberger,
2012). Naturally, after identification of these
variants, attempts have been made to create
mice with corresponding mutations; how-
ever, surprisingly, introducing PD-related
mutations to mice resulted in only a mild
neurodegeneration phenotype.
Alpha-Synuclein
The majority of transgenic mouse models
focused on the expression of wild-type or
mutant α-synuclein, and have been exten-
sively reviewed elsewhere (Breger & Fuzzati
Armentero, 2019; Koprich, Kalia, & Brotchie,
2017; Visanji et al., 2016). Most of these
transgenic mice present very mild, if any, loss
of dopaminergic neurons and many do not de-
velop α-synuclein aggregation (Breger & Fuz-
zati Armentero, 2019). Interestingly, alanine
to threonine substitution at position 53 (A53T)
in human α-synuclein is associated with famil-
ial PD (Polymeropoulos et al., 1997), whereas
mouse wild-type α-synuclein normally has
threonine at position 53, which is not caus-
ing a PD phenotype. Further, a substrain of
C57BL/6J mice (C57Bl/6OlaHsd) possesses
a chromosomal deletion of α-synuclein lo-
cus and the animals appear phenotypically
normal (Specht & Schoepfer, 2001). Thus,
species-specific differences between mice and
humans in sensitivity of dopaminergic neu-
rons to α-synuclein mutations clearly exist.
Recently, a novel transgenic mouse model ex-
pressing truncated α-synuclein under control
of the rat TH promoter on α-synuclein-null
genetic background has been created. These
mice develop age-dependent loss of nigral
dopaminergic neurons and striatal fibers,
progressive accumulation of α-synuclein
inclusions, reduced striatal dopamine content
and release, and locomotor abnormalities,
recapitulating key features of PD. Moreover,
the authors demonstrated application of this
model for pre-clinical drug development,
showing that a small molecule modulator of
α-synuclein aggregation rescued dopaminer-
gic neurons and behavior phenotype in these
mice (Wegrzynowicz et al., 2019).
LRRK2
Several transgenic mouse lines have been
created carrying PD-associated mutations in
LRRK2, but none recapitulate the Parkinso-
nian phenotype observed in human patients
(Bichler, Lim, Zeng, & Tan, 2013; Chen et al.,
2012; Li et al., 2010; Li et al., 2009; Ramonet
et al., 2011; Weng et al., 2016). Bacterial
artificial chromosome (BAC) transgenic mice
overexpressing human LRRK2-R1441G at 5
to 10-fold relative to endogenous levels de-
velop normally, without loss of dopaminergic
neuron numbers or striatal dopaminergic in-
nervation. Nevertheless, compared to control
mice overexpressing wild-type LRRK2 at the
same levels, the mice expressing LRRK2-
R1441G exhibit attenuated dopamine release
and axonal abnormalities, as well as reduced
mobility, which, by 10-12 months of age,
progresses to immobility in most mutant
animals (Li et al., 2009). However, indepen-
dent analysis of the same LRRK2-R1441G
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transgenic mouse line observed gastrointesti-
nal dysfunction from 6 months of age, but
no abnormalities in a battery of behavioral
tests, no changes in learning and memory,
and, contrary to the original data, no signs
of akinesia (Bichler et al., 2013). The cause
of the apparent discrepancy between these
studies remains unclear. In line with the latter
results, knockin mice having endogenous lev-
els of LRRK2 with R1441C mutation appear
normal and, while having impaired dopamine
D2 receptor function, show normal striatal
dopamine levels without dopaminergic neuron
loss up to 2 years of age (Tong et al., 2009).
Similarly, 12-month-old BAC transgenic
mice with strong overexpression of mouse
LRRK2-G2019S exhibit decreased striatal
dopamine content, but no differences in levels,
enzymatic activity, or phosphorylation state of
striatal TH protein, and no loss of dopaminer-
gic neurons. Interestingly, overexpression of
wild-type mouse LRRK2 resulted in elevated
striatal dopamine release, hyperactivity, and
enhanced motor performance (Li et al., 2010).
However, in yet another transgenic model
utilizing human BAC to overexpress wild-
type or LRRK2-G2019S, reduced striatal
dopamine levels without neurodegeneration
have been observed (Melrose et al., 2010).
Similarly, reduced striatal dopamine con-
tent, fragmentation of Golgi in dopaminergic
neurons, and increased microtubule polymer-
ization, as well as motor deficits in the beam
walking and rotarod tests, but no dopaminer-
gic neuron loss have been observed in mice
overexpressing human LRRK2-I2020T under
control of the CMV promoter (Maekawa
et al., 2012). Several other groups attempted
to overexpress wild-type or mutant LRRK2
under control of CMV enhancer/PDGF-β
promoter driving neuron-specific transgene
expression, including dopaminergic neurons
(Liu, Wang, Ma, & Wang, 2004). Transgenic
mice expressing human LRRK2-R1441C
and G2019S at 3-5-fold levels compared to
endogenous LRRK2 exhibit age-related de-
generation of dopaminergic neurons in some
19-20-month-old LRRK2-G2019S, but not
in LRRK2-R1441C mutant animals, without
apparent changes in striatal dopamine concen-
trations or behavioral phenotype (Ramonet
et al., 2011). Expression of human LRRK2-
G2019S caused progressive loss of nigral
dopaminergic neurons and striatal terminals at
12 and 16 months of age, as well as associated
motor deficits in open field and pole climbing
tests (Chen et al., 2012). The same research
group generated LRRK2-R1441C transgenic
mice, using a similar transgenic construct
and observed loss of nigral dopaminergic
neurons, striatal terminals, and motor behav-
ioral deficits in 16-month-old mice (Weng
et al., 2016). However, conditional expres-
sion of human LRRK2-R1441C induced by
Cre recombinase expressed in dopaminer-
gic neurons under control of DAT promoter
[DAT-Cre mice (Turiault et al., 2007)] did not
induce degeneration of dopaminergic neurons
and no motor deficits have been observed
(Tsika et al., 2014). Tetracycline-inducible
overexpression of LRRK2-G2019S also did
not cause neurodegeneration but accelerated
the progression of neuropathological abnor-
malities in A53T α-synuclein transgenic mice
(Lin et al., 2009). However, these results have
also been challenged by later studies failing
to demonstrate the effect of LRRK2 overex-
pression on α-synuclein pathology (Herzig
et al., 2012); the discrepancy is attributed to
cell type and brain region-specific differences
in the transgene expression.
DJ-1
Modeling autosomal recessive mutations
in mice has not resulted in recapitulation
of a Parkinsonian phenotype either. Mice
with a loss-of-function deletion of DJ-1
have impaired nigrostriatal dopaminergic
function, display reduced locomotor and
rearing activity in the open field test at the
age of 11 months, and by 5 months of age,
the males had impairment in the adhesive
tape removal test. However, no differences
in rotarod test, no protein inclusions, and no
dopaminergic neuron loss have been observed
(Chen et al., 2005). Nigrostriatal dopamine
system function appeared normal without
any pathological changes in another DJ-1
knockout model (Chandran et al., 2008).
Careful examination of dopamine dynamics
and electrophysiological studies on acute
striatal slices demonstrated reduced evoked
dopamine overflow, impaired activation of
D2 autoreceptors, and impaired long-term
depression in medium spiny neurons of DJ-1
knockout mice (Goldberg et al., 2005). Inter-
estingly, early onset unilateral degeneration of
nigral dopaminergic neurons and the loss of
noradrenergic neurons in the locus coeruleus
have been observed in a subset of DJ-1 knock-
out mice backcrossed onto a C57Bl/6 genetic
background; however, the molecular mech-
anisms explaining the susceptibility of these
mice to neurodegeneration remain unclear
(Rousseaux et al., 2012). Though not repro-
ducing the neurodegeneration phenotype,
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DJ-1 knockout mice have been instrumental
in studying the functions of the DJ-1 protein,
demonstrating its involvement in scavenging
mitochondrial H2O2 (Andres-Mateos et al.,
2007). In line with these data, DJ-1 knockout
mice have increased sensitivity to MPTP and
oxidative stress (Kim et al., 2005).
PINK1
Similarly, knockout of the mitochondrial
protein kinase PINK1 did not result in a major
neurodegeneration phenotype, though defects
in mitochondrial functions (Gispert et al.,
2009) and impairments of corticostriatal long-
term potentiation and long-term depression
(Kitada et al., 2007) have been observed. Stud-
ies in PINK1 knockout mice demonstrated
the importance of PINK1 protein for normal
calcium-induced mitochondrial permeability
transition and the maintenance of striatal
dopamine levels and turnover. PINK1 dele-
tion affected NF-κB signaling and increased
the levels of both pro-inflammatory and anti-
inflammatory cytokines after induction of
peripheral inflammation (Akundi et al., 2011).
Impaired gait and olfactory dysfunctions and
alterations of mitochondrial fragmentation
have also been demonstrated (Glasl et al.,
2012). Altogether, similar to DJ-1 knock-
out animals, PINK1 knockout mice exhibit
mildly impaired function of the nigrostri-
atal dopamine system and may be useful to
model the prodromal PD stage preceding the
development of neurodegeneration.
Parkin
Despite high initial hopes, knockout of
ubiquitin ligase Parkin in mice did not result
in a robust PD model (Perez & Palmiter,
2005). Nigrostriatal dopamine system deficits
have been observed in Parkin knockout mice
without the loss of dopaminergic neurons
up to 24 months of age (Goldberg et al.,
2003; Itier et al., 2003). A different Parkin
knockout mouse line exhibited reduced life
span, abnormal gait, accumulation of Tau, and
moderate loss of dopaminergic neurons with
aging (Rodriguez-Navarro et al., 2007). In-
terestingly, Parkin deletion resulted in the
degeneration of noradrenergic neurons in the
locus coeruleus and, consequently, a reduc-
tion of the noradrenaline-dependent acoustic
startle response (Von Coelln et al., 2004).
Impaired in vivo dopamine release without
neurodegeneration has been observed in an-
other Parkin knockout model (Oyama et al.,
2010). The presence of mild impairments
in synaptic plasticity affecting learning and
memory in Parkin-deficient mice raised hope
that these animals can be used to model early
prodromal stages of PD (Rial et al., 2014).
However, a careful side-by-side comparative
analysis of Parkin, PINK1, DJ-1 knockout,
and LRRK2-R1441G transgenic mice did
not detect any difference in dopamine release
between these animals and wild-type controls,
suggesting that mutations in these genes are
not sufficient to affect either survival or func-
tion of mouse dopaminergic neurons, at least
in young adult animals (Sanchez et al., 2014).
In an attempt to boost a neurodegenerative
phenotype in Parkin knockout mice, these an-
imals were crossed with other mutant models.
The mice overexpressing Parkin-associated
endothelin receptor-like receptor (Pael-R),
shown to be a Parkin substrate, on a Parkin
knockout background exhibited accumulation
of Pael-R causing increased oxidative and en-
doplasmic reticulum (ER) stress and unfolded
protein response leading to activation of ER-
stress-mediated cell death pathways and
age-related neurodegeneration of dopamin-
ergic neurons (Wang et al., 2008). Similarly,
deletion of Parkin combined with the over-
expression of human mutant α-synuclein
resulted in structural and functional abnor-
malities of mitochondria in neurons and glia
(Schmidt et al., 2011; Stichel et al., 2007).
Interestingly, a BAC transgenic model ex-
pressing C-terminal truncated human mutant
Parkin (Parkin-Q311X) at physiological lev-
els in dopaminergic neurons under control of
the mouse DAT promoter have been created,
aiming to test possible dominant toxic effects
of this Parkin mutation. These mice exhibited
progressive locomotor abnormalities in open
field, beam walking, cylinder, and adhesive
tape removal tests, accumulation of proteinase
K-resistant α-synuclein inclusions, oxidative
protein damage, and age-related loss of nigral
dopaminergic neurons (Lu et al., 2009).
Parkin, PINK1, and DJ-1 proteins form
a ubiquitin E3 ligase complex promoting
ubiquitination and proteasomal degradation
of Parkin substrates. Ubiquitination activ-
ity of this protein complex is reduced after
genetic deletion of PINK1 or DJ-1 (Xiong
et al., 2009). Considering these results and the
absence of dopaminergic neuron degeneration
in single knockout mice, triple Parkin/DJ-
1/PINK1 knockout mice have been created.
However, even this triple knockout did not
result in degeneration of either dopaminergic
neurons in the midbrain or noradrenergic neu-
rons in the locus coeruleus at up to 24 months
of age (Kitada, Tong, Gautier, & Shen, 2009).
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Etiological Models
In parallel with the models based on mu-
tations associated with PD, a number of other
transgenic mouse models have been created
aiming to study the effect of particular genes
on survival and maintenance of dopaminergic
neurons in adult and aged animals. Generally,
these models have been more successful in
recapitulating neurodegeneration and a PD-
like behavioral phenotype. The drawback of
many etiological models is that the effect of
mutations of genes essential for dopamin-
ergic neuron survival is so profound that it
cannot be reversed by experimental treat-
ments, limiting usefulness of these models
for pre-clinical studies. The targeted genes
were either involved in regulating crucial
pro-survival cellular pathways, affected by
aging and/or stress, or deregulated in PD pa-
tients. Interestingly, analysis of heterozygous
deletion mutants for several genes involved
in dopaminergic neuron differentiation have
uncovered their role in adult and aged neu-
rons. For example, heterozygous deletion of
transcription factor Nurr1 led to decreased
evoked dopamine release, depletion of striatal
dopamine levels, and loss of dopaminergic
neurons in aged animals (Zhang, Le, Xie, &
Dani, 2012). Similarly, aged mice with het-
erozygous deletion of Foxa2 developed motor
abnormalities and progressive asymmetric
loss of nigral dopaminergic neurons (Kittappa,
Chang, Awatramani, & McKay, 2007). Mice
heterozygous for Engrailed1 transcription
factor also showed age-related progressive
degeneration of dopaminergic neuron axons
in the dorsal striatum and cell bodies in the SN
(Nordstroma et al., 2015). However, it cannot
be excluded that haploinsufficiency for these
factors already affected dopaminergic neurons
at the embryonic stage and this developmental
abnormality manifested itself as increased
sensitivity to stress and eventual neurodegen-
eration later in life. To overcome this problem,
tamoxifen-inducible CreERT2 recombinase
was expressed under control of the DAT
promoter (DAT-CreERT2) enabling selective
conditional ablation of “floxed” genes in adult
dopaminergic neurons (Engblom et al., 2008).
Several dopaminergic neuron-specific Cre re-
combinase expressing mouse lines (DAT-Cre)
have also been created (Backman et al., 2006;
Ekstrand et al., 2007; Turiault et al., 2007;
Zhuang, Masson, Gingrich, Rayport, & Hen,
2005). Despite concerns about specificity of
Cre expression (Papathanou, Dumas, Pet-
tersson, Olson, & Wallen-Mackenzie, 2019)
and spontaneous tamoxifen-independent
recombination (“leakiness”) of CreERT2
(Kristianto, Johnson, Zastrow, Radcliff, &
Blank, 2017; Sandlesh, Juang, Safina, Hig-
gins, & Gurova, 2018), these mouse lines
have been extremely useful to study functions
of multiple genes in dopaminergic neurons.
For example, analysis of sonic hedgehog
(Shh)/DAT-Cre mice revealed that Shh ex-
pression in dopaminergic neurons is essential
for their maintenance in the adult animals, as
the mutant mice exhibited neurodegeneration,
locomotor, and gait abnormalities (Gonzalez-
Reyes et al., 2012). Similarly, conditional
ablation of Foxa1 and Foxa2 in the adult
Foxa1/Foxa2/DAT-CreERT2 mice resulted
in locomotor impairments, reduced striatal
dopamine, and degeneration of dopaminergic
neurons in aged animals (Domanskyi et al.,
2014). In addition, deletion of Nurr1 in ma-
ture dopaminergic neurons resulted in reduced
striatal dopamine content, axonal dystrophy,
and locomotor phenotype, but was not asso-
ciated with neurodegeneration (Kadkhodaei
et al., 2013). Severe downregulation of the
vesicular monoamine transporter 2 (VMAT2)
in dopaminergic neurons demonstrated its
importance for adult dopaminergic neuron
maintenance. Hypomorphic mice expressing
very low levels of VMAT2 have decreased
striatal dopamine levels, elevated oxidative
stress, locomotor impairments, and neurode-
generation at old age. Importantly, these mice
also show α-synuclein accumulation in nigral
dopaminergic neurons (Caudle et al., 2007).
Mitochondrial dysfunctions have been
associated with PD development and progres-
sion (Park, Davis, & Sue, 2018). MPTP, a
widely used toxin for PD modeling, causes an
effective inhibition of complex I respiration in
dopaminergic neuron mitochondria (Mered-
ith & Rademacher, 2011; Schober, 2004).
In attempts to create a robust and reliable
genetic PD model, several genes important
for mitochondrial function have been tar-
geted. Indeed, dopaminergic neuron-specific
deletion of Cox10 (Cox10/DAT-Cre mice), a
protein essential for functional maturation of
cytochrome c oxidase, caused severe degener-
ation of dopaminergic neuron axons and cell
bodies, neuroinflammation, and depletion of
striatal dopamine with robust and progressive
motor behavioral deficits, resembling ad-
vanced PD. Importantly, motor impairments
could be reverted by L-DOPA or pioglitazone
treatment, demonstrating usefulness of this
PD model for pre-clinical drug testing (Pinto
et al., 2016). However, not all genetic mu-
tations affecting mitochondria resulted in a
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neurodegeneration phenotype. For example,
deletion of Mitofusin 2, which regulates
fusion of outer mitochondrial membrane,
in dopaminergic neurons (Mfn2/DAT-Cre)
caused mitochondrial fragmentation and res-
piratory chain deficiency leading to the loss of
dopaminergic axonal projections in the stria-
tum with severe depletion of striatal dopamine
levels, but no degeneration of nigral dopamin-
ergic neurons (Lee et al., 2012). Surprisingly,
genetic inhibition of mitochondrial complex
I achieved by deletion of one of its subunits,
Ndufs4, in dopaminergic neurons (Ndufs4/
DAT-Cre) did not lead to the loss of nigral
dopaminergic neurons or increased suscep-
tibility to MPTP; however, these mice had
reduced striatal dopamine concentration and
accumulation of phosphorylated α-synuclein
in nigral dopaminergic neurons (Kim et al.,
2015). An interesting approach to induce
mitochondrial DNA damage was achieved by
inducible dopaminergic neuron-specific ex-
pression of PstI endonuclease targeted to the
mitochondria, which caused double-strand
breaks in the mtDNA, depleting its levels,
and leading to the formation of large dele-
tions. These PD-mito-PstI mice exhibited
a progressive age-dependent degeneration
of nigral dopaminergic neurons, depletion
of striatal dopamine, and motor behavioral
abnormalities, which could be reversed with
L-DOPA treatment (Pickrell, Pinto, Hida, &
Moraes, 2011). But perhaps the most success-
ful mitochondrial genetic PD model is the
MitoPark mouse, carrying conditional dele-
tion of mitochondrial transcription factor A
(Tfam) in dopaminergic neurons (Tfam/DAT-
Cre). These mice have dramatically reduced
expression of genes encoded by mitochon-
drial DNA, such as cytochrome c oxidase,
causing respiratory chain deficiency which
leads to the adult-onset progressive locomotor
deficits, loss of dopaminergic neurons and
their axonal projections, and a behavioral
phenotype. The MitoPark mouse is one of the
first genetic models recapitulating most of the
key PD features, as these animals also accu-
mulate intraneuronal inclusions containing
mitochondrial proteins and membrane com-
ponents (Ekstrand & Galter, 2009; Ekstrand
et al., 2007; Galter et al., 2010). Unfortunately,
the inclusions do not contain α-synuclein, and
for that reason the model was criticized as
not faithfully reproducing Lewy body for-
mation (Potashkin, Blume, & Runkle, 2010).
However, a recent study demonstrated that,
in addition to α-synuclein, Lewy bodies also
contain membranes originating from vesicles
and fragmented mitochondria (Shahmora-
dian et al., 2019). Moreover, MitoPark mice
recapitulate the gastrointestinal dysfunction
and gut microbiome changes characteristic
of early PD (Ghaisas et al., 2019). Therefore,
perhaps, the utility of the MitoPark mice as
a robust and reproducible genetic PD model
with a gradually progressing dopaminergic
neurodegeneration phenotype and protein
inclusions is much higher than recognized.
Importantly, behavioral abnormalities in these
mice can be alleviated with L-DOPA, as well
as small molecule drugs, demonstrating that
the MitoPark mouse PD model can be suc-
cessfully used for modeling L-DOPA-induced
dyskinesia or utilized for pre-clinical testing
of novel PD therapies, including cell trans-
plantation (Chen et al., 2018; Ekstrand et al.,
2007; Langley et al., 2017; Shan et al., 2015;
Zhang, Granholm, et al., 2012).
Nucleolar disruption in dopaminergic
neurons has been observed in post-mortem
midbrain sections of PD patients. The hy-
pothesis that age-related nucleolar stress and
deregulation of ribosomal RNA synthesis
can predispose dopaminergic neurons to
degeneration in PD has been directly tested
in TIF-IA/DAT-CreERT2 mice carrying
dopaminergic neuron-specific tamoxifen-
inducible deletion of TIF-IA (also known
as RNA polymerase I-specific transcription
initiation factor, RRN3). The mice exhibited
progressive degeneration of dopaminergic
neurons, reduced striatal dopamine levels, and
behavioral abnormalities (Rieker et al., 2011).
In contrast to PD patients and toxin-induced
mouse PD models, nucleolar integrity was not
affected by DJ-1/PINK1 double knockout,
highlighting the value of the TIF-IA condi-
tional knockout model to study PD-related
nucleolar dysfunction (Evsyukov et al., 2017).
The utility of TIF-IA/DAT-CreET2 mice for
pre-clinical drug testing has recently been
proven by the study showing a neuroprotective
effect of reboxetine, a selective noradrenaline
reuptake inhibitor, on dopaminergic neurons
(Kreiner et al., 2019). These mice have also
been used to demonstrate the neuroprotective
outcome of Akt pathway activation in adult
dopaminergic neurons (Domanskyi et al.,
2011).
Last but not least, the importance of mi-
croRNA biogenesis for dopaminergic neuron
survival and function has been demonstrated
in a series of studies in mice with conditional
knockout of Dicer, a crucial enzyme for
generation of mature microRNAs (Chmielarz
et al., 2017; Kim et al., 2007; Pang et al.,
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2014). The Dicer/DAT-CreERT2 mice show
progressive loss of dopaminergic neurons
and striatal dopamine, leading to strongly
reduced activity and impaired performance
in the open field and rotarod tests, respec-
tively (Chmielarz et al., 2017). Interestingly,
even the heterozygous inducible deletion
of Dicer in dopaminergic neurons led to
reduced concentrations of striatal dopamine
and its metabolites (Chmielarz et al., 2017),
demonstrating that age-related changes in
Dicer and microRNA levels observed in PD
patients (Briggs et al., 2015) can affect func-
tion of dopaminergic neurons and increase
their vulnerability to stress, contributing to
neurodegeneration in PD. In line with this
hypothesis, pharmacological stimulation of
microRNA biogenesis promoted survival
of dopaminergic neurons (Chmielarz et al.,
2017). This is another example illustrating
how the study of an etiological PD model led
to the development of new drug treatments.
In summary, the GWAS-based mouse PD
models (except certain α-synuclein transgenic
mice) have been surprisingly inefficient in
recapitulating human PD features. Why is it
that genetic mutations causing PD in humans
do not recapitulate the disease in the mouse?
Clearly, careful analysis of species-specific
differences between mice and humans, such
as the presence of neuromelanin and dif-
ferences in dopamine metabolism will be
crucial for understanding differential vulner-
ability of dopaminergic neurons in mouse
models versus PD patients. Indeed, a recent
study demonstrated that increase in either α-
synuclein or dopamine levels in mouse DJ-1
knockout dopaminergic neurons promoted
their degeneration and recapitulated human
dopaminergic neuron pathology (Burbulla
et al., 2017). In comparison to GWAS-based
mutants, etiological PD models are much
more successful in recapitulating key PD
features and appear to be more useful for pre-
clinical studies of novel therapies. However, in
order to be relevant for PD, these models need
to target genes and pathways showing age-
and/or disease-related changes in PD patients.
ALPHA-SYNUCLEIN
OVEREXPRESSION MODELS
Adeno-Associated
Virus-Alpha-Synuclein Model
Using adeno-associated virus (AAV) to
overexpress α-synuclein in animals is a pop-
ular model amongst PD researchers (Albert,
Voutilainen, Domanskyi, & Airavaara, 2017).
Most commonly, AAV carrying the human α-
synuclein transgene is stereotaxically injected
unilaterally above the SNpc to overexpress the
α-synuclein protein in the area. Both wild-type
and mutant forms (ex. A53T) of α-synuclein
have been used for this purpose (Decressac,
Mattsson, Lundblad, Weikop, & Bjorklund,
2012; Febbraro et al., 2013) and although the
wild-type form is more often utilized, there
have been effects with overexpression of the
mutated α-synuclein protein as well (Koprich
et al., 2017). The model produces α-synuclein
protein expression in the dopaminergic neu-
rons of the nigrostriatal tract which can cause
loss of TH expression and unilateral motor
deficits (Decressac et al., 2013; Decressac,
Mattsson, & Bjorklund, 2012). While loss of
TH in the SNpc is common in this model,
the outcome of other measures often used in
the field of animal models of PD such as loss
of TH expression in the striatum, dopamine
content levels, and certain motor phenotypes
are less clearly observed or not shown at all
(Albert et al., 2017).
One may attribute different outcomes in
this model to the variety of serotypes, pro-
moters, wild-type versus mutant α-synuclein,
number of particles injected, and time points
used—and this is the case. However, it is
also a pertinent question as to whether the
model in general recapitulates sporadic PD as
it purports to, since in the AAV-α-synuclein
model in rats SNCA (gene encoding α-
synuclein) mRNA is increased (Decressac,
Mattsson, Lundblad, et al., 2012), whereas in
PD patients the mRNA is actually decreased
(Kingsbury et al., 2004). A study confirmed
that this is indeed the case in the model, that
SNCA mRNA is increased in rats and in pa-
tients decreased (Su et al., 2017), concluding
that this is not necessarily the most useful
model of sporadic PD.
In addition to its lack of validity as a
model of the sporadic disease, we have found
that the AAV-α-synuclein model is not ideal
for therapy testing. In our hands, we were
able to repeat published data in terms of
TH downregulation and behavioral deficits on
the cylinder test (Albert et al., 2019); how-
ever, there was large variation between the
animals and little to no correlation between
amount of α-synuclein present, TH, and be-
havior. Testing therapies on this model in
this manner, by measuring typical outcome
measures used in the field, is therefore not
appropriate. One should use other outcome
measures such as different behavioral assays
(Gombash et al., 2013), or a way to measure
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dopaminergic deficits that does not use im-
munohistochemistry such as SPECT/CT, a
combination of single-photon emission com-
puted tomography and computed tomography
with radioligands for DAT, so that animals can
be checked for a lesion during the experiment
(Back et al., 2013). Nevertheless, the AAV-α-
synuclein model can be a good model to eval-
uate compounds that are aiming to enhance
clearance of α-synuclein, or its aggregated
forms, and in fact for this it is rather valuable
(Chmielarz et al., 2019). However, at the mo-
ment many of the outcome measures used in
the model are the same as for toxin models.
While it is possible to use different mea-
surements and techniques to make the AAV-
α-synuclein more successful, this overlooks
a key component of any model: the control.
In an AAV disease model, as with any AAV,
a vector that overexpresses a different protein
to control for unspecific effects of the relevant
disease vector is needed. The protein most of-
ten used in AAV studies is GFP. The GFP used
in biology studies is derived from a species of
jellyfish (Ormo et al., 1996). In addition to the
fact that it is not derived from mammals, it has
been shown to be toxic to dopaminergic neu-
rons in the SNpc of rats when overexpressed
at high levels via AAV (R. L. Klein et al.,
2006). Further, when injected to the striatum
of non-human primates, AAV9-eGFP showed
astrogliosis and microgliosis in the transduced
area, and animals that received the vector to
the cisterna magna showed behavioral deficits
(Samaranch et al., 2014). However, in the
same study, non-human primates receiving
AAV9-hAADC (aromatic L-amino acid de-
carboxylase derived from human) showed
no such gliosis or behavioral phenotype. In
relation to AAV-α-synuclein, experiments
where eGFP is expressed at similar levels to
the α-synuclein resulted in loss of TH-positive
cells in the SNpc in rats (Koprich et al., 2011;
Landeck, Buck, & Kirik, 2016). We observed
a similar effect (Albert et al., 2019), where
there was a loss of TH in the animals in-
jected with AAV-α-synuclein and AAV-eGFP
over multiple experiments and conditions.
Although this is likely a loss of TH phenotype
since we observed the same phenomenon with
AAV-DIO-mCherry which in our experiments
does not express protein since the animals
lack Cre recombinase, and also there was no
global cell loss as evident from Nissl staining.
Therefore, since TH is known to be a highly
regulated enzyme in dopamine synthesis, we
and others would recommend VMAT2 as
a marker of dopaminergic neurons in these
studies (Decressac et al., 2011). And while
it is well-known in the field that decreasing
the titer of AAV-GFP to be lower than AAV-
α-synuclein results in little to no toxicity, we
would ask if this is a relevant control. If un-
specific protein expression is also causing cell
loss similarly to the protein of interest, then the
only thing separating the AAV-α-synuclein
model from a classic toxin model is the
presence of high, non-physiological levels of
α-synuclein protein. One remedy for this is to
use proteins that are derived from mammals
and form oligomers but are not prone to mis-
folding, such as actin or collagen, as controls.
AAV-α-synuclein is a popular model
amongst PD researchers; however, setting
it up needs caution and several modifica-
tions from the current literature for it to be
a useful model. If setting it up for the first
time, outcome measures and controls need
to be carefully considered. And in the end,
this may not remove the variation between
animals or the lack of correlation between
outcome measures—making it difficult to test
new therapies. Additionally, it is questionable
whether the AAV-α-synuclein model in rats
recapitulates the sporadic form of PD.
Preformed Alpha-Synuclein Fibrils
Model
As discussed above, several studies us-
ing different viral vectors were reported to
result in neuronal cell death in the SNpc,
decreased dopamine release in striatum
and motor deficits (Albert et al., 2017;
Visanji et al., 2016). However, overexpres-
sion of α-synuclein relies on very high non-
physiological levels of protein, which cause
cell death due to protein buildup, and, there-
fore, might not mimic sporadic PD pathology.
In addition, α-synuclein overexpression does
not always lead to formation of insoluble
α-synuclein-positive inclusions. As an al-
ternative, a new model using the misfolded
insoluble form of α-synuclein was recently
developed and quickly became popular.
This model utilizes insoluble species of
α-synuclein, which, when injected to the
brain or applied to in vitro cultures, recruit
endogenous α-synuclein and form aggre-
gates in the cell body and neurites, which
are capable of spreading from one neuron to
another (Volpicelli-Daley et al., 2011). Any
effect observed in this model fully depends
on the ability of recombinant α-synuclein
to recruit endogenous α-synuclein, since no
Lewy body-like pathology was observed in α-
synuclein knockout neurons after preformed
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fibrils (PFFs) inoculation. Importantly, fibrils
recruit specifically α-synuclein: solubility
of β-synuclein was shown to be unaltered
(Luk, Kehm, Carroll, et al., 2012; Luk, Kehm,
Zhang, et al., 2012).
The first report demonstrating that exoge-
nous insoluble α-synuclein fibrils are capable
of modeling Lewy body-like pathology was
published by Luk et al. (2009). They showed
that purified human wild-type α-synuclein fib-
rils recruit endogenous α-synuclein causing its
aggregation and formation of Lewy body-like
inclusions positive for key Lewy body mark-
ers observed in PD patients, such as ubiquitin
and pS129-α-synuclein immunoreactivity. A
later study showed that fibrils are internalized
by neurons and capable of propagating in the
cells, causing disruption of normal neuronal
function and eventual death in vitro. After
these initial reports, the first in vivo study fol-
lowed, demonstrating that PFFs are capable to
induce Lewy body-like pathology in wild-type
mice (Luk, Kehm, Carroll, et al., 2012). This
study demonstrated that a single intrastriatal
PFFs injection caused extensive spread of α-
synuclein inclusions in a time-dependent man-
ner, involving striatum, cortex, olfactory bulb,
thalamus, and importantly SNpc. In addition,
Lewy body-like pathology was accompanied
by decreased striatal dopamine content at 3
months and loss of TH-positive neurons in the
SNpc at 6 months, as well as impairment of
motor behavior. Several other groups were us-
ing a similar approach with similar outcomes.
The Abdelmotilib et al. (2017) study reported
vast expansion of Lewy body-like pathology
in the cortex and SNpc and dopamine neu-
ron loss at 6 months after intrastriatal PFFs
injection in mice and rats. Importantly, this
study also demonstrated that the effect can
be animal strain-dependent. Karampetsou
et al. (2017) demonstrated Lewy body-like
pathology spread to SNpc, dopamine neuron
loss, and some motor deficits in mice as early
as 2 months after injection of phosphorylated
at S129 PFFs into the striatum. Similar re-
sults were demonstrated in marmosets and
cynomolgus monkeys injected with PFFs into
striatum. It was reported that Lewy body-like
inclusions were generated in TH-positive neu-
rons in the SNpc, coinciding with significant
neuronal loss (Chu et al., 2019; Shimozawa
et al., 2017).
Additionally, other sites of PFF inocula-
tion were also reported. Studies in PD brains
suggest that α-synuclein pathology spreads to
the brainstem from the olfactory bulb and/or
from gastrointestinal tract via enteric vagus
nerve and then spreads further with disease
progression. Rey et al. (2016) created a mouse
model of prodromal PD by injecting fibrillar
α-synuclein into the olfactory bulb. After
12 months, pS129-positive inclusions were
detected throughout the brain in connected
areas, including the SNpc. However, there
was no further progression of Lewy body-like
pathology at 23 months when pS129 was
propagation studied after injecting PFFs into
the mouse gastric wall (Rey et al., 2018;
Uemura et al., 2018). The study demonstrated
formation of pS129-positive aggregates in
the dorsal motor nucleus of the vagus nerve,
which could be prevented by vagotomy. How-
ever, the pathology did not spread beyond the
dorsal nucleus up to 12 months and the num-
ber of pS129-positive neurons decreased over
time. A similar model in rats and non-human
primates also only showed minor Lewy body-
like pathology in rats at 1 month, which was
gone over time despite persistent pathology
in the enteric nervous system. Nor was Lewy
body-like pathology (Rey et al., 2018; Uemura
et al., 2018) detected in non-human primates
at 12 months, despite extensive spread of
α-synuclein pathology in the enteric nervous
system (Manfredsson et al., 2018).
Although dopaminergic neurons are the
primary group of cells affected in PD, Lewy
bodies are also found in other brain areas
including the hippocampus and cortex. It
is proposed that α-synuclein aggregation in
these areas may be related to the development
of cognitive deficits observed in some PD
patients. Therefore, induction of Lewy body-
like pathology with PFFs in hippocampal and
cortical neurons was used as a model to study
this aspect of PD. For example, Nouraei et al.
(2018) injected PFFs into mice hippocampus
and caused formation of α-synuclein-positive
inclusions, which were insufficient to cause
hippocampal cell death, but their expansion
was negatively correlated with memory ca-
pacity. Blumenstock et al. (2017) reported
that α-synuclein accumulation induced by
intrastriatal injection of PFFs caused dendritic
spine loss in the mouse somatosensory cortex.
Typically, prion diseases are distinguished
by the presence of various protein strains that
can exhibit differences in various properties,
such as cell binding and penetration, propen-
sity to induce aggregation and neurotoxicity
(Bousset et al., 2013). Different species of
α-synuclein were proposed to cause different
synucleinopathies, and therefore, were used as
a model of α-synuclein pathology. α-synuclein
monomers and oligomers were shown to cause
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protein aggregation neither in vitro nor in vivo
despite spreading more efficiently than insolu-
ble α-synuclein species (Gribaudo et al., 2019;
Luk et al., 2009; Peelaerts et al., 2015). Pee-
laerts et al. (2015) also reported that another
insoluble form of recombinant α-synuclein,
named ribbons, cause rather Lewy neurite-like
filamentous phenotype, while fibrils demon-
strated the highest neurotoxic potential. To
contrast, Gribaudo et al. (2019) assessing
propagation of fibrils and ribbons in human-
derived neurons demonstrated that both rib-
bons and fibrils form similar inclusions that
persist over time and are transferred between
neurons. Both strains have no effect on cell vi-
ability or morphology, but alterations in Ca2+
homeostasis with progression of α-synuclein
aggregation and altered mitochondrial mor-
phology were recorded. However, it is impor-
tant to keep in mind that currently there is no
evidence of different misfolded α-synuclein
species in humans (Bousset et al., 2013).
Some studies combined synthetic α-
synuclein with α-synuclein overexpression
(either transgenic mice or viral overexpres-
sion). For example, Luk, Kehm, Zhang, et al.
(2012) demonstrated that injection of exoge-
nous α-synuclein into the striatum of trans-
genic mice expressing human α-synuclein
with A53T mutation accelerated development
of α-synuclein pathology and significantly re-
duced survival. Thakur et al. (2017) reported
that combining PFFs with AAV-mediated α-
synuclein overexpression in the SNpc results
in more rapid development of Lewy body-like
pathology in rats, accompanied by dopamin-
ergic neuron loss, decreased dopamine levels,
and impaired motor behavior. AAV-mediated
overexpression of α-synuclein in rat prefrontal
cortex combined with PFFs seeding results
in extensive α-synuclein aggregation pathol-
ogy and significant impairment of cognitive
functions, such as memory, attention, and
inhibitory control (Espa et al., 2019). Along
with these studies, α-synuclein pathology
development was accelerated by combining
AAV-mediated α-synuclein overexpression
and α-synuclein insoluble species (both fibrils
and ribbons) inoculation in mice. Combined
treatment increased the number of cells with
α-synuclein-positive inclusions and increased
TH-positive cell loss (while none caused
neuronal death by themselves). Interestingly,
combination of AAV-α-synuclein and ribbons
also caused sparse α-synuclein aggregates in
oligodendrocytes, raising further questions
about α-synuclein species-specific toxicity
(Peelaerts et al., 2015).
In conclusion, artificial insoluble α-
synuclein strains persist as a valuable alter-
native to the viral vector-induced α-synuclein
pathology model. However, despite the fact
that the phenotype generated by this model
develops much slower than in viral overex-
pression or toxin models, it is still faster than
in clinical α-synuclein pathology which is
believed to take approximately 5-10 years.
Therefore, data interpretation from this artifi-
cial model should be taken with caution, since
they might not reflect the events of the clinical
disease (Okuzumi et al., 2018).
CELLULAR MODELS OF
DOPAMINERGIC DEGENERATION
AND PROTEIN AGGREGATION
Animals are currently the only way we
can model complex interactions between
different cell types and structures in the brain.
However, while being simplified, in vitro
cellular models offer advantages in speed,
cost, ease of manipulation, and decreased an-
imal use (Kepp, Galluzzi, Lipinski, Yuan, &
Kroemer, 2011). Cellular models are ideally
suited for the investigation of intracellular
mechanisms underlying pathological condi-
tions and screening of protective compounds
(Falkenburger, Saridaki, & Dinter, 2016;
Kepp et al., 2011; Lopes, Bristot, da Motta,
Parsons, & Klamt, 2017). Moreover, with cur-
rent advances in automated microscopy and
the advent of machine learning-based image
analysis, in vitro cellular models are becom-
ing capable of delivering multimodal data at
an unprecedented scale (Boutros, Heigwer, &
Laufer, 2015). Below, we will briefly describe
the most commonly utilized cell types and
methodology for modeling PD in vitro.
Cells used in Modeling PD Pathology
In Vitro
Cell lines like SH-SY5Y, PC12, MN9D,
and CSM14.1 recapitulate some markers
of dopaminergic neurons (Falkenburger
& Schulz, 2006) such as the presence of
dopamine, DAT, TH, and D2R. Expression
levels of these proteins are usually low unless
the cells are further differentiated. The pro-
cedure of differentiation can vary but often
depends on treatment with neurotrophic fac-
tors like BDNF, GDNF or NGF, and retinoic
acid. The disadvantages of cell line differenti-
ation are costs, time, and variability between
and even within labs. Still, obtained cells will
only superficially resemble neurons and usu-
ally do not recapitulate one of the hallmarks
of dopaminergic neurons—spontaneous
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peacemaking. Since our understanding of PD
etiology is limited (Surmeier, Obeso, & Hall-
iday, 2017), we cannot purposely recapitulate
all pathological processes leading to neuronal
degeneration in this disease. Therefore, it
is tenable to utilize models recapitulating
physiological properties of dopaminergic
neurons, assuming that they will best reca-
pitulate pathological processes in PD. Recent
advancements in using cell lines for mod-
eling PD have come in the development of
Lund human mesencephalic (LUHMES) cells
(Scholz et al., 2011). Differentiated LUHMES
cells show a more neuronal phenotype and
might exhibit electrophysiological properties
resembling dopaminergic neurons, including
spontaneous activity (Scholz et al., 2011).
However, their disadvantages are much higher
difficulty and cost of the culture.
The main advantage of using cell lines is
the possibility to acquire a virtually unlimited
amount of relatively homogeneous cells. This
is most important when employing assays
relying on measurements of bulk signal from
entire culture wells (like MTT or LDH assays)
and/or for acquiring of protein and RNA sam-
ples for biochemical studies. However, many
measurements can now be done on a per-cell
basis utilizing fluorescent dyes, immunoflu-
orescent staining, and genetically encoded
reporters (Delenclos et al., 2019; Falken-
burger et al., 2016; Kepp et al., 2011). These
advancements come from the application of
automated microscopy capable of scanning
96- or 384-multiwell plates within hours or
even minutes. Moreover, quantification of ob-
tained data can be automatized with available
open-source software (McQuin et al., 2018)
or custom algorithms (Kraus & Frey, 2016).
Automated microscopy is ideally suited for
measurements in primary mesencephalic neu-
ronal cultures. Such cultures usually contain
5%-10% of bona fide dopaminergic neurons
(Chmielarz et al., 2017; Planken, Porokuokka,
Hanninen, Tuominen, & Andressoo, 2010).
These cells, albeit isolated from embryos, ma-
ture in culture after several days, and exhibit
all the main characteristics of neuronal cells
and specifically of dopaminergic neurons.
They grow large axonal trees, release and
uptake dopamine, and show spontaneous
peacemaking linked with Ca2+ fluctuations.
Additionally, primary dopaminergic neu-
rons are exceptionally vulnerable to insults
used to model PD, further confirming their
relevance in modeling the disease. Utilizing
early post-natal cultures, it is even possible to
separately culture dopaminergic neurons from
the substantia nigra and the ventral tegmental
area (Sulzer, Trudeau, & Rayport, 2008). The
disadvantage of primary cultures of dopamin-
ergic neurons is that isolation of RNA or
protein is not possible without an addi-
tional sorting step, and efficient gene transfer
requires the use of lentiviral vectors. Nonethe-
less, primary cultures remain probably the
best option for experiments on dopaminergic
neurons, rather than dopamine-neuron resem-
bling cells, bearing in mind that there might be
differences due to animal origin of these cells.
A feasible option to study PD in vitro on
human dopaminergic neurons came recently
with the advent of induced pluripotent stem
cells (iPSC) and advancement in protocols
of obtaining iPSC-derived dopaminergic
neurons (Chambers et al., 2009). It is now
possible to get relatively highly enriched
populations of iPSC derived cells showing all
major characteristics of dopaminergic neurons
(Burbulla et al., 2017). These cells give hope
for increased translational relevance since
they display vulnerabilities not observed in
mouse dopaminergic neurons (Burbulla et al.,
2017) and excitingly, can be derived from PD
patients’ biopsies. IPSC-derived dopaminer-
gic neurons will probably be the ultimate in
vitro cellular model for PD. However, there
are still many hurdles to overcome before
their widespread use. They are extremely la-
borious and expensive to obtain and maintain,
requiring highly trained personnel. Moreover,
variability between different batches of differ-
entiated cells can be high, although the ability
to generate isogenic controls with gene editing
is a very elegant way to obtain control cells.
Induction of Pathology In Vitro
Modeling dopaminergic neuron degenera-
tion in vitro utilizes largely the same methods
as described in previous paragraphs. Neuro-
toxins, mostly 6-OHDA and MPTP, have been
commonly utilized, as well as rotenone and
lactacystin (Falkenburger & Schulz, 2006).
Of significant note is that specificity of 6-
OHDA and MPTP largely depends on specific
uptake, and hence, the expression of DAT,
which can vary between batches of differen-
tiated cell lines, and therefore, might affect
the obtained results. In addition, screened
compounds might affect DAT activity giving
false-positive results (Falkenburger & Schulz,
2006). Moreover, the doses of toxin used can
have a major impact on the study outcome
since it was demonstrated that upon low toxin
doses dopaminergic neurons in vitro die by
apoptosis. In contrast, higher doses induce
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necrosis (Venderova & Park, 2012). This fact
raises some concerns about the relevance of
toxin-induced cell death to the demise of hu-
man dopaminergic neurons in PD. In primary
cultures and for iPSC-derived cells, neuronal
death can be assessed by directly quantifying
surviving dopaminergic neurons using, e.g.,
TH immunostaining, and additionally investi-
gated by specific cell death assays (Kepp et al.,
2011). For cell lines of higher homogeneity
bulk assays such as LDH release or the MTT
assay can be used (Kepp et al., 2011).
Aggregation and accumulation of α-
synuclein in vitro can be modeled with over-
expression or α-synuclein PFFs, as described
in previous paragraphs. Cell lines generally
do not express high levels of endogenous α-
synuclein, not surprisingly since it is a protein
mainly involved in synaptic function. There-
fore, cell lines usually require overexpression
of α-synuclein to observe aggregation, leaving
some concerns about physiological validity
(Delenclos et al., 2019; Falkenburger et al.,
2016). In contrast, robust aggregation of
endogenous α-synuclein can be observed
in primary neuronal cultures (Volpicelli-
Daley, Luk, & Lee, 2014) upon addition of
α-synuclein fibrils. Induction of this pathol-
ogy is more robust in more mature neuronal
cultures, probably due to a higher number
of connections formed, and thus, higher α-
synuclein expression (Volpicelli-Daley et al.,
2014). For iPSC-derived neurons, induction of
α-synuclein aggregation with fibrils might re-
quire a prolonged period of culture since their
maturation is slower. Cell death in in vitro
α-synuclein aggregation models is not very
pronounced (Volpicelli-Daley et al., 2014).
However, primary cultures are perfectly suited
to observe the sequence of events leading to
α-synuclein aggregation and for screening of
compounds targeting α-synuclein, since α-
synuclein aggregation can be easily quantified
after immunofluorescent staining.
MORPHOMETRIC ANALYSIS IN
PD MODELS
Immunohistochemistry
Analysis of the lesion, regardless of used
toxin, is usually done by staining the free-
floating or paraffin sections cut from the
animals’ midbrain for dopaminergic neuron
markers, most commonly TH, DAT, and/or
VMAT2 (Kirik et al., 1998; Penttinen, Parkki-
nen, Blom, et al., 2018). The visualization
is usually achieved either by colorimetric
or fluorescent tags. Colorimetric, such as
diaminobenzidine (DAB), does not require
activation with specific light sources and is,
therefore, best when one does not have fluo-
rescence microscopes or scanners available.
However, using infrared secondary antibodies
can provide greater specificity and linearity,
especially when brain tissue often has aut-
ofluorescence at shorter wavelengths. Both
colorimetric (DAB) and immunofluorescent
stainings (AF680 and AF800) have been
used in rat brain sections when analyzing
6-OHDA lesions and the variations in optical
density measurements were similar (Pentti-
nen, Parkkinen, Blom, et al., 2018). Another
advantage of using infrared wavelengths
combined with whole slide scanners is multi-
plexing from the same sample, as colorimetric
has fewer options for dual or triple stainings.
Quantification of Dopaminergic
Neurites and Cell Bodies
Stereology with the optical fractionator
method and unbiased counting rules has been
the backbone of cell counting for the past
few decades (West, Slomianka, & Gunder-
sen, 1991). Stereology, however, is time-
consuming and often requires a specialized
microscope and software for efficient and un-
biased counting. New computational methods
have enhanced counting, e.g., implementing
MatLab in calculations provide similar re-
sults as obtained with the optical fractionator
unbiased counting (Penttinen et al., 2016).
However, this still requires manual labor, and
newer methods aim to automatize counting.
The most recent advances use advanced AI
algorithms, such as convoluted neural net-
work (CNN)-based algorithms for counting
dopaminergic neurons from images (Pentti-
nen, Parkkinen, Blom, et al., 2018). Counting
achieved with the CNN correlates highly with
counting done by stereology and offers a
workload reducing option for counting cells.
Average optical density measurements
have been used in quantifying striatal in-
nervation of dopaminergic neurons in animal
models of PD for the past few decades (Burke,
Cadet, Kent, Karanas, & Jackson-Lewis,
1990). Dopaminergic neurites from midbrain
sections are labelled with their respective
markers as described in the “immunohisto-
chemistry” paragraph of this article, and the
striatal sections are imaged with microscopes
or scanners. From the photomicrographs,
the optical densitometric measurements of
the stainings are done with various image
analysis software, such as ImageJ (or FIJI),
ImagePro or e.g., Olympus software when
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implementing IR-staining (Penttinen, Parkki-
nen, Blom, et al., 2018). In unilateral models,
the measurements are done from both hemi-
spheres to assess the size of the lesion by
comparing the lesioned side to the control
side and subtracting the background stain,
usually measured from the corpus callosum
as there are no TH positive fibers there.
FUTURE PERSPECTIVES
In academic research, we have a repro-
ducibility crisis and it has been estimated
that most biomedical academic work cannot
be reproduced (Eisner, 2018). In addition,
higher impact factor of journals correlates
with poorer reproducibility of studies. It is
the purpose of academic science to do inno-
vative research developing completely new
concepts, but nonetheless we need to have in-
tegrity, especially principal investigators, and
pass this along to young researchers. It cannot
be that we force PhD students or post-doctoral
scientists to prove that a concept or treatment
is working just so that they can graduate, get
the next job, and simultaneously make the
laboratory look prosperous. One way to tackle
this problem and to increase the quality of ex-
perimental PD research is by following the ex-
ample of the stroke field, namely, develop and
adhere to a set of guidelines for conducting
pre-clinical studies on PD models. We could
implement Stroke Therapy Academic Indus-
try Roundtable (STAIR)-like criteria for PD if
both academic and industry experts come to-
gether. The other way to solve the problem is
to promote hypothesis-driven research. If the
research results are important to understand
basic biology of the human dopaminergic
system, it does not matter whether they are
negative or positive in terms of developing
new treatments and moving the field forward.
As reviewed above, in many cases the
originally promising results of multiple ani-
mal PD models have not been reproduced in
subsequent studies, both on behavioral and
cellular levels. Seemingly easy to perform
behavioral tests are especially sensitive to a
variety of factors; critically, sufficient number
of animals per experimental group should be
used (Hanell & Marklund, 2014). Journals
and their editors have an important role in
improving the reproducibility of experimental
PD research. Journals disseminate the results
to other researchers and they need to take
more responsibility for this issue. There are
some journals that have done this already and
taken the reproducibility of published data as
their key area to improve, and implemented
a statistical editor to review the statistics,
experimental designs, and data presentation.
Students and researchers at all levels should
improve their knowledge and educate more
on biostatistics. These aspects do not only
concern PD research, but most preclinical and
biological studies as well.
It is important to understand what the cur-
rent state of α-synuclein biology is. For exam-
ple, while many studies show that α-synuclein
is a disordered protein, these are based on
experiments where α-synuclein is produced
in E. coli where it is well-known that mam-
malian proteins do not fold similarly as they
do in mammalian cells. Whether endogenous
α-synuclein is monomeric or oligomeric still
needs to be clarified–and in relation to this,
agreement on nomenclature is still lacking.
One should be clear when discussing so-called
“toxic” species of α-synuclein, does it refer to
α-synuclein that is causing cell death, as this
appears to not always be the case, and whether
this oligomeric species is endogenous protein
or it is aggregated. Authors should be clear
when discussing these topics.
It is rather clear that proteostasis prob-
lems and aggregated α-synuclein have a role
in the disease progression. Decreasing α-
synucleinopathy and aggregated α-synuclein
is, thus, a very important aspect of developing
new therapies for PD. Since α-synuclein is
also found in blood and may reflect the con-
centration found in the brain, what is clearly
needed is quantifiable measures for clinical
outcome. We need PD biomarkers that can be
quantified in a linear manner and that predict
the outcome of the disease onset or progres-
sion, and moreover, the same outcome should
be able to be measured from disease models
and with reporters in cell cultures as well,
demonstrating that it has a biological basis.
For GWAS found genes there are numerous
possibilities to affect dopaminergic neurode-
generation than having a singular cause
for degeneration. Past studies in mice have
shown that these genes alone are not the only
cause for the PD phenotype resulting from
degeneration of nigrostriatal dopaminergic
neurons. In the future, it would be important
to study the basic biology of these genes
and corresponding proteins in the concept
of human dopaminergic neurons, and, more
importantly what are the effects of mutation
at the neurovascular unit.
Recent progress in the generation of stem
cell-derived midbrain dopaminergic progeni-
tors essentially solved the problem of human
cell availability and ethical concerns, enabling
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studies of dopaminergic neurons derived from
human stem cells in culture (Grealish et al.,
2014; Nolbrant, Heuer, Parmar, & Kirkeby,
2017). The research focus may be shifting to-
wards studying possible neuroprotective treat-
ments in human dopaminergic neurons, which
offer alternative and, possibly, a better option
to model PD. Indeed, dopaminergic neurons
differentiated from both familial and idio-
pathic PD patient-derived induced pluripotent
stem (iPS) cells successfully recapitulate
increased stress sensitivity, mitochondrial
and synaptic dysfunctions, abnormal neu-
ronal morphology, and pathological protein
aggregation [reviewed in Beevers, Caffrey,
and Wade-Martins (2013); Li, Jiang, Zhang,
and Feng (2018); and Mishima, Fujioka,
Fukae, Yuasa-Kawada, and Tsuboi (2018)].
However, while differentiated cells acquire
a dopaminergic neuron phenotype, they are
essentially embryonic or early postnatal (La
Manno et al., 2016), and, though more mature
neurons might be possible to obtain by purifi-
cation (Sandor et al., 2017), iPS cell-derived
dopaminergic neurons do not fully recapitu-
late the properties of the adult nigral dopamin-
ergic neurons degenerating in PD patients.
Midbrain organoids can potentially offer
a better model with the additional advantage
of recapitulating the interaction between glia
cells and neurons (Smits et al., 2019). How-
ever, the protocols for robust and reproducible
differentiation of midbrain organoids suitable
for discovery and testing of new neuroprotec-
tive treatments are not yet developed. Though
it has recently been demonstrated that human
organoids can be successfully transplanted to
the adult mouse brain (Mansour et al., 2018),
human organoids do not offer a possibility
to study the effects of experimental neu-
rorestorative treatments on a motor behavior
phenotype.
Development of humanized models based
on transplantation of human midbrain neuron
precursors to the mice in which the endoge-
nous dopaminergic system is severely lesioned
appears to be a promising option for PD mod-
eling. Having human dopaminergic neurons in
the brain with correct cells surrounding them
is an approach that should be used in future
studies. One can even have human dopamin-
ergic neurons together with human astrocytes.
After transplantation to the midbrain, a pro-
portion of human embryonic stem cell-derived
dopaminergic progenitors will differentiate
to nigral dopaminergic neurons, integrate
into appropriate neuronal circuits, and re-
grow axons to innervate their natural targets
(Cardoso et al., 2018; Grealish et al., 2014). It,
therefore, may be possible to obtain mice with
human dopaminergic neurons, correctly dif-
ferentiated and integrated into host neuronal
circuits, essentially replacing the endogenous
dopaminergic system. A similar strategy has
already been successfully implemented to
obtain humanized mice with brains chimeric
for human glia (Windrem et al., 2014).
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